FDA Letter API

Vapor Unlimited, LLC d/b/a Fogworks

Letter data

Company
Vapor Unlimited, LLC d/b/a Fogworks
Recipient
Trevor Campbell | Vapor Unlimited, LLC d/b/a Fogworks | 32733 Eiland Blvd. | Ste 102 | Wesley Chapel | , | FL | 33545 | United States | vaporunlimtedllc@gmail.com
Issue date
2018-11-06
Posted date
Not available
FDA office
Center for Tobacco Products
Subject
Not available
Product
Tobacco
CMS ID
562953
Reference number
1800941
FEI
Not available
Inspection dates
2018-09-13 to 2018-10-16

Normalized citations

21 CFR: None found

21 U.S.C.: None found

Related FDA links

No related FDA letter link is present in the source index.

Full source text

CLOSEOUT LETTER Vapor Unlimited, LLC d/b/a Fogworks MARCS-CMS 562953 — November 06, 2018 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UPS and Electronic Mail Reference #: 1800941 Product: Tobacco Recipient: Recipient Name Trevor Campbell Vapor Unlimited, LLC d/b/a Fogworks 32733 Eiland Blvd. Ste 102 Wesley Chapel , FL 33545 United States vaporunlimtedllc@gmail.com Issuing Office: Center for Tobacco Products 10903 New Hampshire Avenue Silver Spring , MD 20993 United States Dear Trevor Campbell: On September 12, 2018, the United States Food and Drug Administration's (FDA) Center for Tobacco Products (CTP) issued you a Warning Letter informing you that your Candy King Sour Worms e-liquid product is misbranded under section 903(a)(1) and/or 903(a)(7)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because its labeling and/or advertising is false or misleading. Specifically, FDA determined that the labeling and/or advertising of your Candy King Sour Worms e-liquid is misleading under section 903(a)(1) and/or 903(a)(7)(A) of the FD&C Act because it causes the product to imitate food products, particularly ones that are marketed toward, and/or appealing to, children. On September 13, 2018, September 17, 2018, and September 27, 2018, you sent FDA a response to the Warning Letter, and we held teleconferences on September 13, 2018 and October 16, 2018 to discuss the Warning Letter and your response. In response to the Warning Letter, you stated that you implemented corrective actions to address the violation identified in the Warning Letter. Based on our evaluation, it appears that you have taken steps to address the violations identified in the Warning Letter. We note that you may have other tobacco products with labeling and/or advertising that causes the product to be misbranded for similar reasons to those discussed above. You are responsible for taking any necessary actions to bring your tobacco products into compliance with the requirements of the law. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure sustained compliance with the FD&C Act and its implementing regulations or with other relevant legal authority. This letter also will not preclude any regulatory action should violations be observed in the future. Should you have any questions or concerns, please contact me at (301) 796-9235 or by email at elenita.ibarrapratt@fda.hhs.gov . Sincerely, /S/ Ele lbarra-Pratt Division Director Office of Compliance and Enforcement Center for Tobacco Products VIA UPS and Electronic Mail cc: Azim Chowdhury Keller and Heckman LLP 1001 G Street NW, Suite 500 West Washington, DC 20001 chowdhury@khlaw.com Registration Private Domains By Proxy, LLC fogworks.org@domainsbyproxy.com GoDaddy.com, LLC abuse@godaddy.com Content current as of: 04/11/2019 Regulated Product(s) Tobacco